Prescription Medicines
Valtrep Plus Tab.
- Product Category
- Complex hypertension treatment
- Active Ingredients
- Valsartan, hydrochlorothiazide
- Appearance
- Light pink, oval, film-coated tablets
- Reimbursement Code
- 648103110
01 / 02
1. Composition and Strength : 1 tablet
- Active ingredient: Valsartan (USP) ---------- 80mg
Hydrochlorothiazide (EP) — 12.5 mg
- Additives (tar color aluminum lake): Red No. 40, Yellow No. 5
- Other additives: microcrystalline cellulose, magnesium stearate, opadry pink (03B44038), low-substituted hydroxypropyl cellulose, colloidal silicon oxide,
Hydroxypropyl cellulose
2. Efficacy/Effectiveness
Essential hypertension whose blood pressure is not adequately controlled with monotherapy
3. Usage/Dosage
○ Adult
The recommended dose is valsartan 80mg/hydrochlorothiazide 12.5mg, 1 tablet once a day. It can be taken with or without meals and taken with a small amount of water.
Valsartan 160 mg/hydrochlorothiazide 12.5 mg is applied when valsartan 160 mg/hydrochlorothiazide 12.5 mg is prescribed for lowering blood pressure.
The maximum antihypertensive effect is reached after 2–4 weeks.
○ Patients with renal impairment
No dose adjustment is necessary for patients with mild to moderate renal impairment (creatinine clearance rate of 30 mL/min or more).
○ Patients with liver impairment
In patients with mild to moderate hepatic impairment without cholestasis, valsartan should not be used in excess of 80 mg per day.
4. Precautions for use
1. Warning
When drugs that act directly on the renin-angiotensin-aldosterone system (RAAS) are administered to pregnant women, damage and even death may occur in the fetus and newborn. Dozens of such cases have been reported worldwide, even in patients taking ACE inhibitors. Therefore, if pregnancy is confirmed, administration of this drug should be discontinued immediately.
(Refer to the ‘Administration for pregnant and lactating women’ section).
2. Do not administer to the following patients.
1) Patients with or history of hypersensitivity to this drug, its components, or sulfonamide drugs
2) Women who are pregnant or may be pregnant (refer to the ‘Administration to pregnant and lactating women’ section)
3) Valsartan is contraindicated in the following cases:
Patients with severe liver dysfunction, biliary cirrhosis, biliary obstruction, and bile secretion arrest
4) Hydrochlorothiazide is contraindicated in the following cases:
(1) Patients with severe renal impairment (creatinine clearance rate less than 30 mL/min) or acute renal failure (renal function may worsen).
(2) Conditions that increase potassium loss (e.g., salt-losing nephropathy), patients with pre-renal (psychogenic) renal dysfunction
(3) Patients being treated for refractory hypokalemia, hyponatremia, hypercalcemia, and symptomatic hyperuricemia (patients with gout or uric acid and a medical history) or patients with a clear decrease in sodium and potassium in body fluids (may worsen electrolyte malfunctions such as hyponatremia and hypokalemia).
(4) Patients with untreated Addison's disease and lithium combination treatment
(5) Patients with anuria or patients on dialysis (the effect of this drug cannot be expected)
5) Patients suffering from hereditary angioedema or who developed angioedema by taking ACE inhibitors or angiotensin II receptor antagonists in the past
6) Combined use with aliskiren-containing preparations in patients with diabetes or moderate to severe renal impairment (glomerular filtration rate <60mL/min/1.73m2)
3. Administer with caution to the following patients.
1) Patients with changes in electrolytes
2) Patients with sodium and/or fluid deficiency
3) Patients with renal impairment
4) Patients with liver impairment
5) Systemic lupus erythematosus patients
6) Patients with acute angle-closure glaucoma
7) Patients with cerebrovascular disorders (excessive drop in blood pressure may cause cerebral blood flow failure and worsen the condition.)
8) Patients on low-salt therapy (may cause hyponatremia)
9) Patients with severe vascular cirrhosis or cerebral arteriosclerosis (rapid diuresis may cause rapid decrease in plasma volume and blood concentration, resulting in thromboembolism.)
10) Patients who have diabetes themselves or whose parents or siblings have gout, diabetes, or hyperuricemia (hyperuricemia and hyperglycemia may cause gout or diabetes to worsen or become active).
11) Patients with diarrhea and vomiting (electrolyte malfunction may occur)
12) Patients with hyperparathyroidism (serum calcium may increase)
13) Patients taking digitalis, corticosteroids, or ACTH (the blood pressure lowering effect of this drug may be enhanced).
14) Patients after sympathectomy (the blood pressure lowering effect of this drug may be enhanced.)
15) Elderly people
16) Patients after heart failure or myocardial infarction: Administration of angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensin receptor antagonists (ARB) to patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system (RAAS) (e.g., patients with severe heart failure) is associated with oliguria and/or progressive azotemia and (rarely) acute renal failure and/or death. Evaluation of patients after heart failure or myocardial infarction should always include evaluation of renal function.
17) Dual blockade of the renin-angiotensin-aldosterone system (RAAS): Concurrent use with other drugs that affect the renin-angiotensin-aldosterone system (RAAS), such as angiotensin receptor antagonists (ARBs), ACE inhibitors, or aliskiren, is not recommended.
18) Non-melanoma skin cancer (NMSC)
Two epidemiological studies based on the Danish National Cancer Registry reported an increased risk of non-melanoma skin cancer, including basal cell and squamous cell carcinoma, with increasing cumulative exposure to hydrochlorothiazide. The photosensitizing effects of hydrochlorothiazide may contribute to the development of non-melanoma skin cancer.
Inform patients taking hydrochlorothiazide about the risk of non-melanoma skin cancer. Advise them to check their skin regularly for new lesions and report any suspicious skin lesions. Recommend preventive measures to minimize the risk, including limiting exposure to sunlight and ultraviolet radiation and using appropriate protection when exposed. Suspicious skin lesions should be examined promptly, including by biopsy where appropriate. Reconsider the use of hydrochlorothiazide in patients with a history of non-melanoma skin cancer.
19) This drug contains Yellow No. 5 (Sunset Yellow FCF), so administer with caution to patients who are hypersensitive to this ingredient or have a history of allergy.
4. Adverse reactions
1) Valsartan-hydrochlorothiazide complex
(1) The safety of this drug was evaluated in more than 4,300 patients. Adverse reactions were usually transient and mild.
The following adverse reaction table is based on three controlled clinical trials conducted on a total of 7,616 patients (4,372 patients administered this drug). The incidence of adverse reactions with this drug was similar to that with placebo. All adverse reactions with an incidence of 1% or higher for this drug are included in the following table, regardless of causal relationship with the test drug. (See table-attached document)
* Contains any combination of valsartan 80mg, 160mg, 320mg and hydrochlorothiazide 12.5mg, 25mg.
(2) Other: Adverse reactions less than 1% include abdominal pain, epigastric pain, blurred vision, visual abnormalities, anxiety, arthritis, bronchitis, acute bronchitis, chest pain, orthostatic dizziness, dry mouth, indigestion, difficulty breathing, erectile dysfunction, gastroenteritis, hyperhidrosis, hypoesthesia, insomnia, hypokalemia, hypotension, influenza, muscle spasm, muscle sprain, nausea, nasal congestion, nasal bleeding, Sore throat, otitis media, limb pain, paresthesia, sore throat, fever, sinus congestion, sinusitis, drowsiness, leg cramps, frequent urination, palpitations, rash, ligament sprain, syncope, tachycardia, tinnitus, urinary tract infection, viral infection, edema, peripheral edema, asthenia, dizziness, etc., and the causal relationship with this drug has not been determined.
(3) Overseas post-marketing surveillance results showed that the following adverse reactions were very rare: angioedema, rash, itching, other hypersensitivity/allergic reactions including serum sickness and vasculitis, hyperkalemia, hair loss, impaired renal function, and muscle pain. Several cases of hydrochlorothiazide-induced pulmonary edema accompanied by granulocyte infiltration and IgG accumulation in the alveolar membrane have been reported. Non-cardiogenic pulmonary edema may occur as a rare immunologically specific reaction to hydrochlorothiazide.
(4) In clinical trials conducted overseas (Japan), adverse reactions were reported in 288 out of 656 cases (43.9%) in patients administered valsartan-hydrochlorothiazide combination, and the serious adverse reactions are as follows.
① Anaphylaxis-like symptoms (frequency unknown): Since anaphylaxis-like symptoms may occur, observe thoroughly, and if abnormalities appear, stop administration and take appropriate measures.
② Angioedema (frequency unknown): Symptoms such as swelling of the face, lips, pharynx, and tongue may appear. Observe thoroughly, and if any abnormalities appear, stop administration and take appropriate measures.
③ Hepatitis (frequency unknown): Hepatitis may occur, so observe thoroughly, and if abnormalities appear, stop administration and take appropriate measures.
④ Renal failure (frequency unknown): Since renal failure may occur, observe thoroughly, and if abnormalities appear, stop administration and take appropriate measures.
⑤ Hyperkalemia (frequency unknown): Severe hyperkalemia may occur, so observe thoroughly, and if abnormalities appear, discontinue administration and take appropriate measures.
⑥ Hyponatremia (frequency unknown): Hyponatremia may occur accompanied by malaise, loss of appetite, nausea, vomiting, and impaired consciousness, so observe thoroughly and if any abnormalities appear, discontinue administration and take appropriate measures (easily occurs in elderly people).
⑦ Shock, syncope, loss of consciousness (all frequencies unknown): Shock, syncope due to a decrease in blood pressure, or loss of consciousness may occur, so observe thoroughly, and if any abnormalities appear, stop administration and take appropriate measures. Particularly in patients receiving strict salt restriction therapy or antihypertensive diuretics, the patient's condition must be carefully observed.
⑧ Agranulocytosis, decrease in leukocytes, decrease in platelets (all frequencies unknown): Agranulocytosis, decrease in leukocytes, and decrease in platelets may occur, so observe thoroughly and if abnormalities appear, stop administration and take appropriate measures.
⑨ Aplastic anemia, hemolytic anemia (both frequency unknown): Severe blood disorders may occur, so observe thoroughly, and if abnormalities appear, discontinue administration and take appropriate measures.
⑩ Necrotizing vasculitis (frequency unknown): Necrotizing vasculitis may occur, so observe thoroughly, and if abnormalities appear, discontinue administration and take appropriate measures.
⑪ Toxic epidermal necrolysis (Riel syndrome) (frequency unknown): Toxic epidermal necrolysis (Riel syndrome) may occur, so observe thoroughly, and if any abnormalities appear, stop administration and take appropriate measures.
⑫ Interstitial pneumonia (frequency unknown): Interstitial pneumonia may occur accompanied by fever, cough, difficulty breathing, chest X-ray abnormalities, etc. If abnormalities appear, discontinue administration and take appropriate measures such as administration of corticosteroids.
⑬ Pulmonary edema (frequency unknown): Pulmonary edema may occur, so observe thoroughly, and if abnormalities appear, stop administration and take appropriate measures.
⑭ Exacerbation of systemic lupus erythematosus (frequency unknown): As systemic lupus erythematosus may worsen, observe thoroughly, and if any abnormalities appear, discontinue administration and take appropriate measures.
⑮ Hypoglycemia (frequency unknown): Hypoglycemia may occur, so observe thoroughly, and if feelings of weakness, hunger, cold sweat, tremors of the hands, decreased concentration, convulsions, or impaired consciousness appear, stop administration and take appropriate measures (easily occurs in patients undergoing diabetes treatment).
⑯ Rhabdomyolysis (frequency unknown): Rhabdomyolysis, which is characterized by muscle pain, weakness, elevated creatine kinase (CK), and elevated myoglobin in the blood or urine, may occur. Therefore, observe thoroughly, and if any abnormalities appear, stop administration and take appropriate measures.
(5) Domestic post-marketing survey results
As a result of a post-marketing use results survey conducted on 725 people over 6 years for re-examination in Korea, the case rate of adverse reactions was reported to be 2.62% (19 cases/725 cases) regardless of causal relationship, and among these, 1.79% (13 cases/725 cases) were found to have a causal relationship with this drug. Headache, increased AST, dizziness, palpitations, and indigestion occurred in 0.28% (2 cases) each, and edema, asthenia, hypertriglyceridemia, increased creatine kinase (CK), and cough appeared in 0.14% (1 case). An increase in creatine kinase was reported as a new adverse reaction that did not appear in pre-marketing clinical trials.
2) The following adverse reactions were reported when valsartan was administered alone.
(1) Blood and lymphatic system: Unexplained decrease in hemoglobin and hematocrit, thrombocytopenia
(2) Immunity: Other hypersensitivity/allergic reactions, including serum sickness of unknown frequency
(3) Metabolism and nutrition: Unknown increase in serum potassium, hyponatremia
(4) Ear and labyrinth: uncommon vertigo
(5) Blood vessels: vasculitis of unknown frequency
(6) Gastrointestinal tract: uncommon abdominal pain
(7) Liver and biliary tract: Unknown increase in liver function level
(8) Skin and subcutaneous tissue: unknown frequency of angioedema, rash, itching, bullous dermatitis
(9) Kidney and urinary system: unknown incidence of renal failure
Regardless of the causal relationship with this drug, the following symptoms were reported during clinical trials: arthralgia, asthenia, back pain, diarrhea, dizziness, headache, insomnia, decreased libido, nausea, edema, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, and viral infection.
Intestinal angioedema has been reported during post-marketing use (very rarely).
3) The following adverse reactions were reported when thiazide diuretics, including hydrochlorothiazide, were administered alone.
(1) Electrolyte and metabolic abnormalities: very often (especially at high doses) hypokalemia, elevated blood lipids, frequent hyponatremia, hypomagnesemia and hyperuricemia, rarely hypercalcemia, very rarely hypochloremic alkalosis may appear, may change glucose tolerance, and cause increases in serum cholesterol, triglycerides and uric acid levels. In rare cases, hyperglycemia, diabetes, and worsening of diabetic metabolism may occur (refer to the cautionary administration section).
(2) Skin: Frequently urticaria and other types of skin rash, rarely photosensitivity reaction, very rarely necrotizing vasculitis and toxic epidermal necrolysis (Riel syndrome), cutaneous lupus erythematosus reaction, recurrence of cutaneous lupus erythematosus.
(3) Digestive system: frequent loss of appetite, mild nausea and vomiting, rarely abdominal discomfort, constipation, diarrhea, gastrointestinal discomfort, very rarely pancreatitis.
(4) Liver: rarely, intrahepatic cholestasis or jaundice
(5) Circulatory system: frequent orthostatic hypotension (may be worsened by alcohol, anesthetics, or sedatives), rarely cardiac arrhythmia.
(6) Central nervous system: loss of sensation or sedation, rarely headache, dizziness, sleep disturbance, depression, abnormal sensation
(7) Sense organs: Rarely visual impairment (may occur mainly in the first week of treatment).
(8) Blood system: rarely thrombocytopenia (sometimes accompanied by purpura), very rarely leukopenia, agranulocytosis, bone marrow dysfunction, hemolytic anemia
(9) Respiratory system: In very rare cases, acute respiratory distress syndrome (ARDS) may occur.
(10) Others: Frequent erectile dysfunction, very rarely hypersensitivity reactions, pneumonia, and respiratory distress including pulmonary edema.
(11) Adverse drug reactions from overseas post-marketing experience (frequency unknown): acute renal failure, renal failure, aplastic anemia, erythema multiforme, fever, muscle spasms, asthenia, acute angle-closure glaucoma, choroidal effusion.
5. General precautions
1) There are no studies on the effect of this drug on driving or operating machinery, but it should be taken into account that dizziness or drowsiness may occur when driving or operating machinery.
2) Symptomatic hypotension: Patients receiving this drug should be informed of the precautions that dizziness may occur, especially during the first few days of treatment, and should be instructed to notify their doctor if dizziness occurs. Patients should also be advised that inadequate fluid administration, excessive sweating, diarrhea, or vomiting may cause excessive drops in blood pressure, leading to dizziness and syncope.
3) Potassium supplementation: Patients receiving this drug should be instructed not to use potassium supplements or potassium-containing salts without consulting their doctor.
4) Patients with renal artery stenosis: As serum creatinine and blood urea may increase, this drug should not be used in patients with bilateral or unilateral renal artery stenosis or in patients with short stature with stenosis.
5) Thiazide diuretics may cause new hypokalemia or worsen existing hypokalemia. Caution should be exercised when administering thiazide diuretics to patients with severe potassium deficiency (e.g., patients with salt-losing nephropathy and prerenal (psychogenic) renal dysfunction).
If hypokalemia is accompanied by clinical symptoms (e.g. muscle weakness, paresis, or electrocardiographic changes), administration of this drug should be discontinued.
Thiazide diuretics are recommended to be administered after corrective treatment in cases of hypokalemia and accompanying hypomagnesemia. Blood levels of potassium and magnesium should be checked regularly. All patients receiving thiazide diuretics should be monitored for electrolyte imbalances, especially potassium.
Thiazide diuretics may cause new hyponatremia and hypochloremic alkalosis or worsen existing hyponatremia. Hyponatremia with neurological symptoms (nausea, progressive disorientation, apathy) has been observed in isolated cases. Regular monitoring of serum sodium concentration is recommended.
6) In patients who have severe sodium deficiency and/or volume deficiency due to high-dose diuretics, symptomatic hypotension may rarely occur in the early stages of treatment with this drug. Therefore, this drug must be administered after correcting for sodium and body fluid deficiency, and if not, it must be administered under the supervision of a medical professional. If low blood pressure occurs, have the patient lie down in an upright position and, if necessary, inject physiological saline solution by drip. Continue drug administration after blood pressure stabilizes.
7) No dosage adjustment is necessary when administering to patients with mild to moderate renal impairment (creatinine clearance ≥ 30mL/min). Because this drug contains hydrochlorothiazide, this drug is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min). Thiazide diuretics can cause azotemia in patients with chronic kidney disease. Regular monitoring of serum potassium, creatinine, and uric acid levels is recommended when this drug is used in patients with renal impairment.
8) Renal transplant patients: There is no safety data on the use of this drug in patients who have recently undergone renal transplantation.
9) No dose adjustment is necessary when administering this drug to patients with mild to moderate hepatic impairment, but it is advisable not to exceed 80 mg per day of valsartan. In patients with liver dysfunction or advanced liver disease, thiazide diuretics should be used with caution because even slight changes in fluid and electrolyte balance can cause hepatic coma.
10) Thiazide diuretics can cause or worsen systemic lupus erythematosus.
11) Thiazide diuretics, including hydrochlorothiazide, can alter glucose tolerance and cause increases in serum cholesterol and triglycerides. Like other diuretics, hydrochlorothiazide may increase serum uric acid levels by decreasing the clearance of uric acid, cause or worsen hyperuricemia, and may cause gout in susceptible patients. In diabetic patients, dose adjustment of insulin or oral hypoglycemic agents may be necessary.
Thiazide diuretics may slightly increase blood calcium concentration by reducing urinary calcium excretion even when there is no abnormality in calcium metabolism. Because hydrochlorothiazide can increase serum calcium levels, caution should be exercised when administering it to patients with hypercalcemia. Cases that do not respond to discontinuation of thiazide diuretics or show significant hypercalcemia of 12 mg/dL or more may be due to hypercalcemia due to other causes unrelated to thiazide diuretics.
Pathological changes in the parathyroid glands along with hypercalcemia and hypophosphatemia have been observed in some patients who were continuously treated with thiazide diuretics. If hypercalcemia occurs, a parathyroid function test is required. Thiazide diuretics should be discontinued before performing a parathyroid function test. Thiazide diuretics may reduce serum protein-bound iodine levels without signs of thyroid dysfunction.
12) Photosensitivity reaction: Cases of photosensitivity reaction have been reported with thiazide diuretics. If a photosensitivity reaction occurs during treatment, it is recommended to discontinue treatment. If re-administration of thiazide diuretics is necessary, sunlight or artificial UVA shading is recommended.
13) Hydrochlorothiazide and sulfonamide cause acute transient myopia, acute angle-closure glaucoma, and choroidal effusion. Deterioration of vision or eye pain has an acute onset and typically occurs within hours to weeks after starting treatment. A history of sulfonamide or penicillin allergy may be a risk factor for developing acute angle-closure glaucoma. Untreated acute angle-closure glaucoma can lead to permanent vision loss.
Primary treatment is to stop hydrochlorothiazide as soon as possible. If intraocular pressure is not controlled, immediate medical or surgical treatment needs to be considered.
14) Acute respiratory toxicity
Very rare cases of severe acute respiratory toxicity, including acute respiratory distress syndrome (ARDS), have been reported after taking hydrochlorothiazide. Pulmonary edema typically develops within minutes to hours after administration. Symptoms at onset include dyspnea, fever, pulmonary deterioration and hypotension. If ARDS is suspected, discontinue this medicine and provide appropriate treatment.
Hydrochlorothiazide should not be administered to patients who have previously experienced ARDS after taking hydrochlorothiazide.
15) Intestinal angioedema has been reported in patients receiving angiotensin II receptor antagonists. These patients presented with abdominal pain, nausea, vomiting, and diarrhea. Symptoms resolved after discontinuation of angiotensin II receptor antagonist. If intestinal angioedema is diagnosed, treatment should be discontinued and appropriate monitoring should be conducted until symptoms completely resolve.
6. Interaction
1) The following interactions may occur with valsartan/hydrochlorothiazide.
(1) Lithium: When lithium preparations are co-administered with ACE inhibitors, angiotensin II receptor antagonists, or thiazide diuretics, a reversible increase in serum lithium concentration and lithium toxicity has been reported. Because thiazide diuretics reduce the renal clearance of lithium, the risk of lithium toxicity may increase with these drugs. Co-administration of this drug and lithium is not recommended and should only be administered under the strict supervision of a physician. If co-administration of lithium is absolutely necessary, it is recommended to monitor the serum concentration of lithium during the co-administration period.
2) The following interactions may occur due to valsartan.
(1) When valsartan was administered alone, no clinically significant interactions were observed with the following drugs. : Cimetidine, warfarin, furosemide, digoxin, atenolol, indomethacin, hydrochlorothiazide, amlodipine, glibenclamide
(2) Potassium: Concomitant use with potassium-sparing diuretics, potassium supplements, potassium-containing salts, or other drugs that can change serum potassium levels (e.g. heparin) is not recommended.
(3) Nonsteroidal anti-inflammatory drugs (NSAIDs): The antihypertensive effect of angiotensin II receptor antagonists may be reduced when administered simultaneously with NSAIDs (e.g., aspirin COX-2 inhibitor as anti-inflammatory therapy). In particular, the risk of kidney function deterioration may increase in elderly patients, patients lacking body fluids (including patients taking diuretics), or patients with reduced kidney function. Therefore, monitoring of renal function is recommended when starting valsartan or changing the administration method in patients taking NSAIDs.
(4) Because valsartan is not metabolized to a significant level, drug-drug interactions due to induction or inhibition of metabolism by the CYP450 enzyme system are not expected to occur clinically. Despite being strongly bound to plasma proteins, valsartan did not show any interaction at this level with a series of molecules that bind strongly to proteins, such as diclofenac, furosemide and warfarin in in vitro experiments.
(5) Transporters: An in vitro study using human liver tissue showed that valsartan is a substrate for the liver uptake transporter OATP1B1 and the liver efflux transporter MRP2. Coadministration with uptake transporter inhibitors (rifampicin, cyclosporine) or efflux transporter inhibitors (ritonavir) may increase systemic exposure of valsartan.
(6) Dual blockade of the renin-angiotensin system (RAAS) by co-administration of angiotensin receptor antagonists (ARBs), ACE inhibitors, or aliskiren is associated with an increased risk of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy with these drugs. In patients receiving this drug concomitantly with other drugs that act on RAAS, blood pressure, renal function, and electrolytes should be closely monitored. Do not administer this drug and aliskiren-containing preparations together in patients with diabetes or moderate to severe renal impairment (glomerular filtration rate <60mL/min/1.73m2).
3) The following interactions may occur due to the thiazide diuretic, one of the main ingredients of this drug.
(1) NSAIDs and COX-2 selective blockers: Co-administration with NSAIDs (e.g. salicylic acid derivatives, indomethacin) may weaken the diuretic effect and antihypertensive effect of thiazide diuretics. If hypovolemia occurs as a complication, acute renal failure may occur.
(2) Drugs that affect serum potassium levels: The hypokalemic action of diuretics may be increased by concomitant administration with potassium-excreting diuretics (e.g., furosemide), corticosteroids, ACTH, amphotericin, carbenoxolone, penicillin G and salicylic acid derivatives, or antiarrhythmic drugs.
(3) Ion exchange resin: The absorption of thiazide diuretics, including hydrochlorothiazide, is reduced by cholestyramine and colestipol.
(4) Skeletal muscle relaxants: Thiazide diuretics can enhance the action of skeletal muscle relaxants such as curare derivatives.
(5) Antidiabetic agents: Thiazide diuretics may change glucose tolerance, so the dosage of insulin or oral antidiabetic drugs may need to be adjusted. When hydrochlorothiazide causes functional renal failure, it must be administered with caution because concurrent administration with metformin may increase the risk of lactic acidosis.
(6) Amantadine: Co-administration with thiazide diuretics (including hydrochlorothiazide) may increase the risk of adverse reactions caused by amantadine.
(7) Anticholinergic drugs: The bioavailability of thiazide diuretics can be increased by combined use with anticholinergic drugs (e.g. atropine, biperiden) because gastrointestinal motility is reduced and gastric emptying time is slowed. Conversely, gastrointestinal motility agents such as cisapride may reduce the bioavailability of thiazide diuretics.
(8) Methyldopa: Hemolytic anemia has been reported when methyldopa and hydrochlorothiazide are used together.
(9) Vitamin D: When thiazide diuretics are used together with vitamin D or calcium salts, serum calcium levels may increase.
(10) Cyclosporine: Concurrent use with cyclosporine may increase the risk of hyperuricemia and gout-type complications.
(11) Alcohol, barbitrate, or narcotics: Concurrent administration with alcohol, barbitrate, or narcotics may increase the occurrence of orthostatic hypotension.
(12) Amines that increase blood pressure: Hydrochlorothiazide can reduce the response of amines that increase blood pressure, such as noradrenaline. However, the clinical significance was not clear and did not appear to be sufficient to limit the use of amines that increase blood pressure.
(13) Digitalis glycosides: Hypokalemia or hypomagnesemia caused by thiazide diuretics more easily causes cardiac arrhythmia caused by digitalis.
(14) Drugs that affect serum sodium levels: Hyponatremia may occur in patients taking hydrochlorothiazide and carbamazepine together. Therefore, these patients should be informed of the possibility of developing hyponatremia and monitored appropriately.
(15) Other antihypertensive drugs: Thiazide diuretics enhance the antihypertensive action of other antihypertensive drugs (e.g., guanethidine, methyldopa, beta-blockers, vasodilators, calcium channel blockers, ACE inhibitors, angiotensin II receptor antagonists, and direct renin blockers (DRIs)).
(16) Allopurinol: Co-administration with thiazide diuretics (including hydrochlorothiazide) may increase the incidence of hypersensitivity reaction to allopurinol.
(17) Antitumor drugs (e.g., cyclophosphamide, methotrexate): Concurrent administration with thiazide diuretics (including hydrochlorothiazide) may reduce renal excretion of cytotoxic drugs and thus enhance the myelosuppressive effect.
(18) Calcium salts: Concurrent administration of thiazide diuretics may cause hypercalcemia by increasing calcium reabsorption in the tubules.
(19) Diazoxide and beta-blockers: Thiazide diuretics may increase the hyperglycemic effect of diazoxide. Concomitant use of beta-blockers and thiazide diuretics may increase the risk of hyperglycemia.
(20) Iodine contrast media: In case of dehydration caused by diuretics, the risk of acute renal failure increases, especially when high doses of iodine agents are used together. Rehydration is required prior to administration.
7. Administration to pregnant and lactating women
1) Because of the mechanism of action of angiotensin II receptor antagonists, the risk to the fetus cannot be ignored. There are reports that exposure to ACE inhibitors (a specific group of drugs that act on the renin-angiotensin-aldosterone system (RAAS)) during the second and third trimesters of pregnancy causes fetal development damage and death. Additionally, retrospective data suggest that use of ACE inhibitors in the first trimester of pregnancy is associated with a potential risk of birth defects.
Fetal renal perfusion is established in the second trimester of pregnancy and is influenced by the renin-angiotensin system, so taking valsartan during the second or third trimester increases the risk. The use of drugs that act directly on the renin-angiotensin system during the second and third trimesters of pregnancy has been shown to be associated with fetal and neonatal harm, including hypotension, neonatal cranial hypoplasia, anuria, reversible or irreversible renal failure, and death. Oligohydramnios has been reported and has been shown to be associated with fetal limb contractures, craniofacial malformations, and pulmonary hypoplasia. Premature birth, poor intrauterine growth, and patent ductus arteriosus have also been reported, although the relationship to drug exposure is unclear.
Intrauterine exposure to thiazide diuretics, including hydrochlorothiazide, may cause fetal or neonatal jaundice, thrombocytopenia and other adverse reactions seen in adults. Spontaneous abortion, oligohydramnios and neonatal renal dysfunction have been reported following inadvertent valsartan exposure during pregnancy. All neonates exposed to the medicine in utero should be assessed for urine output, hyperkalemia and blood pressure. If necessary, take medical measures to remove the medicine from the circulation. As with other medicines that act directly on the renin–angiotensin–aldosterone system (RAAS), this medicine must not be used during pregnancy or by women planning pregnancy. Stop treatment immediately if pregnancy is confirmed. In rare cases, affecting fewer than 1 in 1,000 pregnant women, no alternative to a medicine acting on the renin–angiotensin system may be available. In such cases, when prescribing a RAAS-acting medicine to a woman who could become pregnant, the physician must explain its potential risks during pregnancy and perform serial ultrasound examinations to assess the intra-amniotic environment.
If oligohydramnios is observed, this drug should be discontinued except to save the life of the pregnant woman. Depending on the gestational age, contraction stress testing (CST), nonstress testing (NST), or biophysical profiling (BPP) testing may be appropriate. However, patients and doctors should be aware that oligohydramnios may not appear even after irreversible damage has already occurred to the fetus.
Infants who have been exposed in utero to angiotensin II receptor antagonists should be closely monitored for hypotension, oliguria, and hyperkalemia. If oliguria is present, attention should be paid to maintaining blood pressure and renal perfusion. Exchange transfusion or dialysis may be necessary to reverse low blood pressure and replace renal function.
2) It has not been determined whether valsartan is secreted into breast milk in humans, but secretion of valsartan into breast milk was confirmed in tests on rats. Hydrochlorothiazide crosses the placenta and is excreted in breast milk in humans. Therefore, it is not advisable for nursing mothers to use this drug.
3) There is no information on the effects of valsartan or hydrochlorothiazide on human fertility. There is no information on reproductive function in this drug, but non-clinical studies conducted with each component of valsartan and hydrochlorothiazide did not show any effect on reproductive function.
8. Administration to children
Safety and efficacy in children have not been established.
9. Administration to elderly people
In comparative clinical trials of this drug, no overall differences in the efficacy and safety of valsartan-hydrochlorothiazide were observed between elderly and non-elderly groups.
10. Effect on clinical test values
1) A decrease in serum potassium of more than 20% occurred in 3.7% of patients receiving this drug and 3.1% of placebo patients (refer to the cautious administration section).
2) The following results occurred in valsartan monotherapy, but did not occur when administering this drug. : Rarely, a decrease in hemoglobin and hematocrit was observed.
3) The results of the controlled clinical trial showed a significant (>20%) decrease in hematocrit and hemoglobin by 0.8% and 0.4%, respectively. On the other hand, in the case of placebo, both decreased by 0.1%.
4) As a result of the controlled clinical trial, significant increases in serum creatine, potassium, and total bilirubin concentrations were 0.8%, 4.4%, and 6.0% for patients administered valsartan, and 1.6%, 6.4%, and 12.9% for ACE inhibitors. Additionally, in controlled clinical trials, creatinine and BUN increases were observed in 1.9% and 14.7% of patients administered this drug, respectively, and 0.4% and 6.3% of patients treated with placebo, respectively.
5) Occasionally, an increase in liver function test values has been reported with the administration of valsartan.
6) Special monitoring of clinical laboratory values is not necessary for patients with essential hypertension taking this drug.
7) Neutropenia was observed in 0.1% of patients receiving this drug and in 0.4% of patients receiving placebo.
11. Treatment in case of overdose
1) Data on overdose in humans are limited. Symptoms that are likely to appear in overdose are hypotension and tachycardia. : Overdosage of valsartan can cause significant hypotension, which can lead to decreased consciousness, circulatory collapse, and shock. Immediately after taking it, induce vomiting, otherwise, inject saline solution intravenously.
2) Overdosage of hydrochlorothiazide may cause the following symptoms. : Nausea, drowsiness, hypovolemia, electrolyte abnormalities related to arrhythmia, muscle spasms. Measures should be taken depending on the time after overdose and the symptoms or severity of symptoms, but restoration of circulatory stability is most important. If it is immediately after taking it, induce vomiting, and if a long time has passed since taking it, administer an appropriate amount of medicinal charcoal.
3) In case of low blood pressure, place the patient supine and perform plasma replacement as quickly as possible. Valsartan is not removed by hemodialysis due to its strong binding to plasma proteins, but hydrochlorothiazide can be removed by dialysis.
12. Precautions for storage and handling
1) Keep out of reach of children.
2) Store away from moisture.
3) Taking medicine out of its original container and storing it in another container may cause accidents due to misuse of the medicine or cause a decrease in the quality of the medicine, so put it in the original container and keep it tightly closed.
13. Others
In preclinical safety studies of valsartan, hydrochlorothiazide, and valsartan/hydrochlorothiazide using several species of animals, there was no evidence of systemic or specific organ toxicity. High doses of valsartan/hydrochlorothiazide (100/31.25 to 600/187.5 mg/kg) decreased red blood cell counts (erythrocytes, hemoglobin, and hematocrit) and altered renal hemodynamics in rats (moderate to severe increases in blood urea, increases in blood potassium and magnesium, mild increases in urine volume and electrolytes, and slight tubular abnormalities). Basophils, hypertrophy of afferent arteriolar hypertrophy at highest dose). In marmosets (30:9.375 to 400:125mg/kg), the changes were quite similar but more severe. In particular, at high doses, nephropathy occurred in the kidneys, including increases in urea and creatinine.
Hypertrophy of renal juxtaglomerular cells was also observed in both species. All changes are considered to be due to the synergistic (rather than additive, approximately 10-fold potentiating compared to valsartan alone) pharmacological action of valsartan/hydrochlorothiazide, resulting in prolonged hypotension, particularly in marmosets. Therapeutic doses of valsartan-hydrochlorothiazide are unlikely to be associated with renal glomerular hypertrophy in humans. The main preclinical safety findings are due to the pharmacological actions of the drugs, which appear to act synergistically, and there is no evidence of other interactions between the two drugs. In clinical trials, the actions of the two drugs were additive, and preclinical results did not indicate clinical significance.
There was no evidence of valsartan/hydrochlorothiazide interaction, and therefore the combination was not tested for mutagenicity, chromosomal aberrations, or carcinogenicity. However, valsartan and hydrochlorothiazide were tested for mutagenesis, chromosomal abnormality, and carcinogenicity, respectively, and all showed negative results.
5. How to save
Store in an airtight container, avoiding moisture below 30℃.
6. Packaging unit
30 tablets/bottle
7. Expiration date
36 months from date of manufacture
- Active ingredient: Valsartan (USP) ---------- 80mg
Hydrochlorothiazide (EP) — 12.5 mg
- Additives (tar color aluminum lake): Red No. 40, Yellow No. 5
- Other additives: microcrystalline cellulose, magnesium stearate, opadry pink (03B44038), low-substituted hydroxypropyl cellulose, colloidal silicon oxide,
Hydroxypropyl cellulose
2. Efficacy/Effectiveness
Essential hypertension whose blood pressure is not adequately controlled with monotherapy
3. Usage/Dosage
○ Adult
The recommended dose is valsartan 80mg/hydrochlorothiazide 12.5mg, 1 tablet once a day. It can be taken with or without meals and taken with a small amount of water.
Valsartan 160 mg/hydrochlorothiazide 12.5 mg is applied when valsartan 160 mg/hydrochlorothiazide 12.5 mg is prescribed for lowering blood pressure.
The maximum antihypertensive effect is reached after 2–4 weeks.
○ Patients with renal impairment
No dose adjustment is necessary for patients with mild to moderate renal impairment (creatinine clearance rate of 30 mL/min or more).
○ Patients with liver impairment
In patients with mild to moderate hepatic impairment without cholestasis, valsartan should not be used in excess of 80 mg per day.
4. Precautions for use
1. Warning
When drugs that act directly on the renin-angiotensin-aldosterone system (RAAS) are administered to pregnant women, damage and even death may occur in the fetus and newborn. Dozens of such cases have been reported worldwide, even in patients taking ACE inhibitors. Therefore, if pregnancy is confirmed, administration of this drug should be discontinued immediately.
(Refer to the ‘Administration for pregnant and lactating women’ section).
2. Do not administer to the following patients.
1) Patients with or history of hypersensitivity to this drug, its components, or sulfonamide drugs
2) Women who are pregnant or may be pregnant (refer to the ‘Administration to pregnant and lactating women’ section)
3) Valsartan is contraindicated in the following cases:
Patients with severe liver dysfunction, biliary cirrhosis, biliary obstruction, and bile secretion arrest
4) Hydrochlorothiazide is contraindicated in the following cases:
(1) Patients with severe renal impairment (creatinine clearance rate less than 30 mL/min) or acute renal failure (renal function may worsen).
(2) Conditions that increase potassium loss (e.g., salt-losing nephropathy), patients with pre-renal (psychogenic) renal dysfunction
(3) Patients being treated for refractory hypokalemia, hyponatremia, hypercalcemia, and symptomatic hyperuricemia (patients with gout or uric acid and a medical history) or patients with a clear decrease in sodium and potassium in body fluids (may worsen electrolyte malfunctions such as hyponatremia and hypokalemia).
(4) Patients with untreated Addison's disease and lithium combination treatment
(5) Patients with anuria or patients on dialysis (the effect of this drug cannot be expected)
5) Patients suffering from hereditary angioedema or who developed angioedema by taking ACE inhibitors or angiotensin II receptor antagonists in the past
6) Combined use with aliskiren-containing preparations in patients with diabetes or moderate to severe renal impairment (glomerular filtration rate <60mL/min/1.73m2)
3. Administer with caution to the following patients.
1) Patients with changes in electrolytes
2) Patients with sodium and/or fluid deficiency
3) Patients with renal impairment
4) Patients with liver impairment
5) Systemic lupus erythematosus patients
6) Patients with acute angle-closure glaucoma
7) Patients with cerebrovascular disorders (excessive drop in blood pressure may cause cerebral blood flow failure and worsen the condition.)
8) Patients on low-salt therapy (may cause hyponatremia)
9) Patients with severe vascular cirrhosis or cerebral arteriosclerosis (rapid diuresis may cause rapid decrease in plasma volume and blood concentration, resulting in thromboembolism.)
10) Patients who have diabetes themselves or whose parents or siblings have gout, diabetes, or hyperuricemia (hyperuricemia and hyperglycemia may cause gout or diabetes to worsen or become active).
11) Patients with diarrhea and vomiting (electrolyte malfunction may occur)
12) Patients with hyperparathyroidism (serum calcium may increase)
13) Patients taking digitalis, corticosteroids, or ACTH (the blood pressure lowering effect of this drug may be enhanced).
14) Patients after sympathectomy (the blood pressure lowering effect of this drug may be enhanced.)
15) Elderly people
16) Patients after heart failure or myocardial infarction: Administration of angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensin receptor antagonists (ARB) to patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system (RAAS) (e.g., patients with severe heart failure) is associated with oliguria and/or progressive azotemia and (rarely) acute renal failure and/or death. Evaluation of patients after heart failure or myocardial infarction should always include evaluation of renal function.
17) Dual blockade of the renin-angiotensin-aldosterone system (RAAS): Concurrent use with other drugs that affect the renin-angiotensin-aldosterone system (RAAS), such as angiotensin receptor antagonists (ARBs), ACE inhibitors, or aliskiren, is not recommended.
18) Non-melanoma skin cancer (NMSC)
Two epidemiological studies based on the Danish National Cancer Registry reported an increased risk of non-melanoma skin cancer, including basal cell and squamous cell carcinoma, with increasing cumulative exposure to hydrochlorothiazide. The photosensitizing effects of hydrochlorothiazide may contribute to the development of non-melanoma skin cancer.
Inform patients taking hydrochlorothiazide about the risk of non-melanoma skin cancer. Advise them to check their skin regularly for new lesions and report any suspicious skin lesions. Recommend preventive measures to minimize the risk, including limiting exposure to sunlight and ultraviolet radiation and using appropriate protection when exposed. Suspicious skin lesions should be examined promptly, including by biopsy where appropriate. Reconsider the use of hydrochlorothiazide in patients with a history of non-melanoma skin cancer.
19) This drug contains Yellow No. 5 (Sunset Yellow FCF), so administer with caution to patients who are hypersensitive to this ingredient or have a history of allergy.
4. Adverse reactions
1) Valsartan-hydrochlorothiazide complex
(1) The safety of this drug was evaluated in more than 4,300 patients. Adverse reactions were usually transient and mild.
The following adverse reaction table is based on three controlled clinical trials conducted on a total of 7,616 patients (4,372 patients administered this drug). The incidence of adverse reactions with this drug was similar to that with placebo. All adverse reactions with an incidence of 1% or higher for this drug are included in the following table, regardless of causal relationship with the test drug. (See table-attached document)
* Contains any combination of valsartan 80mg, 160mg, 320mg and hydrochlorothiazide 12.5mg, 25mg.
(2) Other: Adverse reactions less than 1% include abdominal pain, epigastric pain, blurred vision, visual abnormalities, anxiety, arthritis, bronchitis, acute bronchitis, chest pain, orthostatic dizziness, dry mouth, indigestion, difficulty breathing, erectile dysfunction, gastroenteritis, hyperhidrosis, hypoesthesia, insomnia, hypokalemia, hypotension, influenza, muscle spasm, muscle sprain, nausea, nasal congestion, nasal bleeding, Sore throat, otitis media, limb pain, paresthesia, sore throat, fever, sinus congestion, sinusitis, drowsiness, leg cramps, frequent urination, palpitations, rash, ligament sprain, syncope, tachycardia, tinnitus, urinary tract infection, viral infection, edema, peripheral edema, asthenia, dizziness, etc., and the causal relationship with this drug has not been determined.
(3) Overseas post-marketing surveillance results showed that the following adverse reactions were very rare: angioedema, rash, itching, other hypersensitivity/allergic reactions including serum sickness and vasculitis, hyperkalemia, hair loss, impaired renal function, and muscle pain. Several cases of hydrochlorothiazide-induced pulmonary edema accompanied by granulocyte infiltration and IgG accumulation in the alveolar membrane have been reported. Non-cardiogenic pulmonary edema may occur as a rare immunologically specific reaction to hydrochlorothiazide.
(4) In clinical trials conducted overseas (Japan), adverse reactions were reported in 288 out of 656 cases (43.9%) in patients administered valsartan-hydrochlorothiazide combination, and the serious adverse reactions are as follows.
① Anaphylaxis-like symptoms (frequency unknown): Since anaphylaxis-like symptoms may occur, observe thoroughly, and if abnormalities appear, stop administration and take appropriate measures.
② Angioedema (frequency unknown): Symptoms such as swelling of the face, lips, pharynx, and tongue may appear. Observe thoroughly, and if any abnormalities appear, stop administration and take appropriate measures.
③ Hepatitis (frequency unknown): Hepatitis may occur, so observe thoroughly, and if abnormalities appear, stop administration and take appropriate measures.
④ Renal failure (frequency unknown): Since renal failure may occur, observe thoroughly, and if abnormalities appear, stop administration and take appropriate measures.
⑤ Hyperkalemia (frequency unknown): Severe hyperkalemia may occur, so observe thoroughly, and if abnormalities appear, discontinue administration and take appropriate measures.
⑥ Hyponatremia (frequency unknown): Hyponatremia may occur accompanied by malaise, loss of appetite, nausea, vomiting, and impaired consciousness, so observe thoroughly and if any abnormalities appear, discontinue administration and take appropriate measures (easily occurs in elderly people).
⑦ Shock, syncope, loss of consciousness (all frequencies unknown): Shock, syncope due to a decrease in blood pressure, or loss of consciousness may occur, so observe thoroughly, and if any abnormalities appear, stop administration and take appropriate measures. Particularly in patients receiving strict salt restriction therapy or antihypertensive diuretics, the patient's condition must be carefully observed.
⑧ Agranulocytosis, decrease in leukocytes, decrease in platelets (all frequencies unknown): Agranulocytosis, decrease in leukocytes, and decrease in platelets may occur, so observe thoroughly and if abnormalities appear, stop administration and take appropriate measures.
⑨ Aplastic anemia, hemolytic anemia (both frequency unknown): Severe blood disorders may occur, so observe thoroughly, and if abnormalities appear, discontinue administration and take appropriate measures.
⑩ Necrotizing vasculitis (frequency unknown): Necrotizing vasculitis may occur, so observe thoroughly, and if abnormalities appear, discontinue administration and take appropriate measures.
⑪ Toxic epidermal necrolysis (Riel syndrome) (frequency unknown): Toxic epidermal necrolysis (Riel syndrome) may occur, so observe thoroughly, and if any abnormalities appear, stop administration and take appropriate measures.
⑫ Interstitial pneumonia (frequency unknown): Interstitial pneumonia may occur accompanied by fever, cough, difficulty breathing, chest X-ray abnormalities, etc. If abnormalities appear, discontinue administration and take appropriate measures such as administration of corticosteroids.
⑬ Pulmonary edema (frequency unknown): Pulmonary edema may occur, so observe thoroughly, and if abnormalities appear, stop administration and take appropriate measures.
⑭ Exacerbation of systemic lupus erythematosus (frequency unknown): As systemic lupus erythematosus may worsen, observe thoroughly, and if any abnormalities appear, discontinue administration and take appropriate measures.
⑮ Hypoglycemia (frequency unknown): Hypoglycemia may occur, so observe thoroughly, and if feelings of weakness, hunger, cold sweat, tremors of the hands, decreased concentration, convulsions, or impaired consciousness appear, stop administration and take appropriate measures (easily occurs in patients undergoing diabetes treatment).
⑯ Rhabdomyolysis (frequency unknown): Rhabdomyolysis, which is characterized by muscle pain, weakness, elevated creatine kinase (CK), and elevated myoglobin in the blood or urine, may occur. Therefore, observe thoroughly, and if any abnormalities appear, stop administration and take appropriate measures.
(5) Domestic post-marketing survey results
As a result of a post-marketing use results survey conducted on 725 people over 6 years for re-examination in Korea, the case rate of adverse reactions was reported to be 2.62% (19 cases/725 cases) regardless of causal relationship, and among these, 1.79% (13 cases/725 cases) were found to have a causal relationship with this drug. Headache, increased AST, dizziness, palpitations, and indigestion occurred in 0.28% (2 cases) each, and edema, asthenia, hypertriglyceridemia, increased creatine kinase (CK), and cough appeared in 0.14% (1 case). An increase in creatine kinase was reported as a new adverse reaction that did not appear in pre-marketing clinical trials.
2) The following adverse reactions were reported when valsartan was administered alone.
(1) Blood and lymphatic system: Unexplained decrease in hemoglobin and hematocrit, thrombocytopenia
(2) Immunity: Other hypersensitivity/allergic reactions, including serum sickness of unknown frequency
(3) Metabolism and nutrition: Unknown increase in serum potassium, hyponatremia
(4) Ear and labyrinth: uncommon vertigo
(5) Blood vessels: vasculitis of unknown frequency
(6) Gastrointestinal tract: uncommon abdominal pain
(7) Liver and biliary tract: Unknown increase in liver function level
(8) Skin and subcutaneous tissue: unknown frequency of angioedema, rash, itching, bullous dermatitis
(9) Kidney and urinary system: unknown incidence of renal failure
Regardless of the causal relationship with this drug, the following symptoms were reported during clinical trials: arthralgia, asthenia, back pain, diarrhea, dizziness, headache, insomnia, decreased libido, nausea, edema, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, and viral infection.
Intestinal angioedema has been reported during post-marketing use (very rarely).
3) The following adverse reactions were reported when thiazide diuretics, including hydrochlorothiazide, were administered alone.
(1) Electrolyte and metabolic abnormalities: very often (especially at high doses) hypokalemia, elevated blood lipids, frequent hyponatremia, hypomagnesemia and hyperuricemia, rarely hypercalcemia, very rarely hypochloremic alkalosis may appear, may change glucose tolerance, and cause increases in serum cholesterol, triglycerides and uric acid levels. In rare cases, hyperglycemia, diabetes, and worsening of diabetic metabolism may occur (refer to the cautionary administration section).
(2) Skin: Frequently urticaria and other types of skin rash, rarely photosensitivity reaction, very rarely necrotizing vasculitis and toxic epidermal necrolysis (Riel syndrome), cutaneous lupus erythematosus reaction, recurrence of cutaneous lupus erythematosus.
(3) Digestive system: frequent loss of appetite, mild nausea and vomiting, rarely abdominal discomfort, constipation, diarrhea, gastrointestinal discomfort, very rarely pancreatitis.
(4) Liver: rarely, intrahepatic cholestasis or jaundice
(5) Circulatory system: frequent orthostatic hypotension (may be worsened by alcohol, anesthetics, or sedatives), rarely cardiac arrhythmia.
(6) Central nervous system: loss of sensation or sedation, rarely headache, dizziness, sleep disturbance, depression, abnormal sensation
(7) Sense organs: Rarely visual impairment (may occur mainly in the first week of treatment).
(8) Blood system: rarely thrombocytopenia (sometimes accompanied by purpura), very rarely leukopenia, agranulocytosis, bone marrow dysfunction, hemolytic anemia
(9) Respiratory system: In very rare cases, acute respiratory distress syndrome (ARDS) may occur.
(10) Others: Frequent erectile dysfunction, very rarely hypersensitivity reactions, pneumonia, and respiratory distress including pulmonary edema.
(11) Adverse drug reactions from overseas post-marketing experience (frequency unknown): acute renal failure, renal failure, aplastic anemia, erythema multiforme, fever, muscle spasms, asthenia, acute angle-closure glaucoma, choroidal effusion.
5. General precautions
1) There are no studies on the effect of this drug on driving or operating machinery, but it should be taken into account that dizziness or drowsiness may occur when driving or operating machinery.
2) Symptomatic hypotension: Patients receiving this drug should be informed of the precautions that dizziness may occur, especially during the first few days of treatment, and should be instructed to notify their doctor if dizziness occurs. Patients should also be advised that inadequate fluid administration, excessive sweating, diarrhea, or vomiting may cause excessive drops in blood pressure, leading to dizziness and syncope.
3) Potassium supplementation: Patients receiving this drug should be instructed not to use potassium supplements or potassium-containing salts without consulting their doctor.
4) Patients with renal artery stenosis: As serum creatinine and blood urea may increase, this drug should not be used in patients with bilateral or unilateral renal artery stenosis or in patients with short stature with stenosis.
5) Thiazide diuretics may cause new hypokalemia or worsen existing hypokalemia. Caution should be exercised when administering thiazide diuretics to patients with severe potassium deficiency (e.g., patients with salt-losing nephropathy and prerenal (psychogenic) renal dysfunction).
If hypokalemia is accompanied by clinical symptoms (e.g. muscle weakness, paresis, or electrocardiographic changes), administration of this drug should be discontinued.
Thiazide diuretics are recommended to be administered after corrective treatment in cases of hypokalemia and accompanying hypomagnesemia. Blood levels of potassium and magnesium should be checked regularly. All patients receiving thiazide diuretics should be monitored for electrolyte imbalances, especially potassium.
Thiazide diuretics may cause new hyponatremia and hypochloremic alkalosis or worsen existing hyponatremia. Hyponatremia with neurological symptoms (nausea, progressive disorientation, apathy) has been observed in isolated cases. Regular monitoring of serum sodium concentration is recommended.
6) In patients who have severe sodium deficiency and/or volume deficiency due to high-dose diuretics, symptomatic hypotension may rarely occur in the early stages of treatment with this drug. Therefore, this drug must be administered after correcting for sodium and body fluid deficiency, and if not, it must be administered under the supervision of a medical professional. If low blood pressure occurs, have the patient lie down in an upright position and, if necessary, inject physiological saline solution by drip. Continue drug administration after blood pressure stabilizes.
7) No dosage adjustment is necessary when administering to patients with mild to moderate renal impairment (creatinine clearance ≥ 30mL/min). Because this drug contains hydrochlorothiazide, this drug is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min). Thiazide diuretics can cause azotemia in patients with chronic kidney disease. Regular monitoring of serum potassium, creatinine, and uric acid levels is recommended when this drug is used in patients with renal impairment.
8) Renal transplant patients: There is no safety data on the use of this drug in patients who have recently undergone renal transplantation.
9) No dose adjustment is necessary when administering this drug to patients with mild to moderate hepatic impairment, but it is advisable not to exceed 80 mg per day of valsartan. In patients with liver dysfunction or advanced liver disease, thiazide diuretics should be used with caution because even slight changes in fluid and electrolyte balance can cause hepatic coma.
10) Thiazide diuretics can cause or worsen systemic lupus erythematosus.
11) Thiazide diuretics, including hydrochlorothiazide, can alter glucose tolerance and cause increases in serum cholesterol and triglycerides. Like other diuretics, hydrochlorothiazide may increase serum uric acid levels by decreasing the clearance of uric acid, cause or worsen hyperuricemia, and may cause gout in susceptible patients. In diabetic patients, dose adjustment of insulin or oral hypoglycemic agents may be necessary.
Thiazide diuretics may slightly increase blood calcium concentration by reducing urinary calcium excretion even when there is no abnormality in calcium metabolism. Because hydrochlorothiazide can increase serum calcium levels, caution should be exercised when administering it to patients with hypercalcemia. Cases that do not respond to discontinuation of thiazide diuretics or show significant hypercalcemia of 12 mg/dL or more may be due to hypercalcemia due to other causes unrelated to thiazide diuretics.
Pathological changes in the parathyroid glands along with hypercalcemia and hypophosphatemia have been observed in some patients who were continuously treated with thiazide diuretics. If hypercalcemia occurs, a parathyroid function test is required. Thiazide diuretics should be discontinued before performing a parathyroid function test. Thiazide diuretics may reduce serum protein-bound iodine levels without signs of thyroid dysfunction.
12) Photosensitivity reaction: Cases of photosensitivity reaction have been reported with thiazide diuretics. If a photosensitivity reaction occurs during treatment, it is recommended to discontinue treatment. If re-administration of thiazide diuretics is necessary, sunlight or artificial UVA shading is recommended.
13) Hydrochlorothiazide and sulfonamide cause acute transient myopia, acute angle-closure glaucoma, and choroidal effusion. Deterioration of vision or eye pain has an acute onset and typically occurs within hours to weeks after starting treatment. A history of sulfonamide or penicillin allergy may be a risk factor for developing acute angle-closure glaucoma. Untreated acute angle-closure glaucoma can lead to permanent vision loss.
Primary treatment is to stop hydrochlorothiazide as soon as possible. If intraocular pressure is not controlled, immediate medical or surgical treatment needs to be considered.
14) Acute respiratory toxicity
Very rare cases of severe acute respiratory toxicity, including acute respiratory distress syndrome (ARDS), have been reported after taking hydrochlorothiazide. Pulmonary edema typically develops within minutes to hours after administration. Symptoms at onset include dyspnea, fever, pulmonary deterioration and hypotension. If ARDS is suspected, discontinue this medicine and provide appropriate treatment.
Hydrochlorothiazide should not be administered to patients who have previously experienced ARDS after taking hydrochlorothiazide.
15) Intestinal angioedema has been reported in patients receiving angiotensin II receptor antagonists. These patients presented with abdominal pain, nausea, vomiting, and diarrhea. Symptoms resolved after discontinuation of angiotensin II receptor antagonist. If intestinal angioedema is diagnosed, treatment should be discontinued and appropriate monitoring should be conducted until symptoms completely resolve.
6. Interaction
1) The following interactions may occur with valsartan/hydrochlorothiazide.
(1) Lithium: When lithium preparations are co-administered with ACE inhibitors, angiotensin II receptor antagonists, or thiazide diuretics, a reversible increase in serum lithium concentration and lithium toxicity has been reported. Because thiazide diuretics reduce the renal clearance of lithium, the risk of lithium toxicity may increase with these drugs. Co-administration of this drug and lithium is not recommended and should only be administered under the strict supervision of a physician. If co-administration of lithium is absolutely necessary, it is recommended to monitor the serum concentration of lithium during the co-administration period.
2) The following interactions may occur due to valsartan.
(1) When valsartan was administered alone, no clinically significant interactions were observed with the following drugs. : Cimetidine, warfarin, furosemide, digoxin, atenolol, indomethacin, hydrochlorothiazide, amlodipine, glibenclamide
(2) Potassium: Concomitant use with potassium-sparing diuretics, potassium supplements, potassium-containing salts, or other drugs that can change serum potassium levels (e.g. heparin) is not recommended.
(3) Nonsteroidal anti-inflammatory drugs (NSAIDs): The antihypertensive effect of angiotensin II receptor antagonists may be reduced when administered simultaneously with NSAIDs (e.g., aspirin COX-2 inhibitor as anti-inflammatory therapy). In particular, the risk of kidney function deterioration may increase in elderly patients, patients lacking body fluids (including patients taking diuretics), or patients with reduced kidney function. Therefore, monitoring of renal function is recommended when starting valsartan or changing the administration method in patients taking NSAIDs.
(4) Because valsartan is not metabolized to a significant level, drug-drug interactions due to induction or inhibition of metabolism by the CYP450 enzyme system are not expected to occur clinically. Despite being strongly bound to plasma proteins, valsartan did not show any interaction at this level with a series of molecules that bind strongly to proteins, such as diclofenac, furosemide and warfarin in in vitro experiments.
(5) Transporters: An in vitro study using human liver tissue showed that valsartan is a substrate for the liver uptake transporter OATP1B1 and the liver efflux transporter MRP2. Coadministration with uptake transporter inhibitors (rifampicin, cyclosporine) or efflux transporter inhibitors (ritonavir) may increase systemic exposure of valsartan.
(6) Dual blockade of the renin-angiotensin system (RAAS) by co-administration of angiotensin receptor antagonists (ARBs), ACE inhibitors, or aliskiren is associated with an increased risk of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy with these drugs. In patients receiving this drug concomitantly with other drugs that act on RAAS, blood pressure, renal function, and electrolytes should be closely monitored. Do not administer this drug and aliskiren-containing preparations together in patients with diabetes or moderate to severe renal impairment (glomerular filtration rate <60mL/min/1.73m2).
3) The following interactions may occur due to the thiazide diuretic, one of the main ingredients of this drug.
(1) NSAIDs and COX-2 selective blockers: Co-administration with NSAIDs (e.g. salicylic acid derivatives, indomethacin) may weaken the diuretic effect and antihypertensive effect of thiazide diuretics. If hypovolemia occurs as a complication, acute renal failure may occur.
(2) Drugs that affect serum potassium levels: The hypokalemic action of diuretics may be increased by concomitant administration with potassium-excreting diuretics (e.g., furosemide), corticosteroids, ACTH, amphotericin, carbenoxolone, penicillin G and salicylic acid derivatives, or antiarrhythmic drugs.
(3) Ion exchange resin: The absorption of thiazide diuretics, including hydrochlorothiazide, is reduced by cholestyramine and colestipol.
(4) Skeletal muscle relaxants: Thiazide diuretics can enhance the action of skeletal muscle relaxants such as curare derivatives.
(5) Antidiabetic agents: Thiazide diuretics may change glucose tolerance, so the dosage of insulin or oral antidiabetic drugs may need to be adjusted. When hydrochlorothiazide causes functional renal failure, it must be administered with caution because concurrent administration with metformin may increase the risk of lactic acidosis.
(6) Amantadine: Co-administration with thiazide diuretics (including hydrochlorothiazide) may increase the risk of adverse reactions caused by amantadine.
(7) Anticholinergic drugs: The bioavailability of thiazide diuretics can be increased by combined use with anticholinergic drugs (e.g. atropine, biperiden) because gastrointestinal motility is reduced and gastric emptying time is slowed. Conversely, gastrointestinal motility agents such as cisapride may reduce the bioavailability of thiazide diuretics.
(8) Methyldopa: Hemolytic anemia has been reported when methyldopa and hydrochlorothiazide are used together.
(9) Vitamin D: When thiazide diuretics are used together with vitamin D or calcium salts, serum calcium levels may increase.
(10) Cyclosporine: Concurrent use with cyclosporine may increase the risk of hyperuricemia and gout-type complications.
(11) Alcohol, barbitrate, or narcotics: Concurrent administration with alcohol, barbitrate, or narcotics may increase the occurrence of orthostatic hypotension.
(12) Amines that increase blood pressure: Hydrochlorothiazide can reduce the response of amines that increase blood pressure, such as noradrenaline. However, the clinical significance was not clear and did not appear to be sufficient to limit the use of amines that increase blood pressure.
(13) Digitalis glycosides: Hypokalemia or hypomagnesemia caused by thiazide diuretics more easily causes cardiac arrhythmia caused by digitalis.
(14) Drugs that affect serum sodium levels: Hyponatremia may occur in patients taking hydrochlorothiazide and carbamazepine together. Therefore, these patients should be informed of the possibility of developing hyponatremia and monitored appropriately.
(15) Other antihypertensive drugs: Thiazide diuretics enhance the antihypertensive action of other antihypertensive drugs (e.g., guanethidine, methyldopa, beta-blockers, vasodilators, calcium channel blockers, ACE inhibitors, angiotensin II receptor antagonists, and direct renin blockers (DRIs)).
(16) Allopurinol: Co-administration with thiazide diuretics (including hydrochlorothiazide) may increase the incidence of hypersensitivity reaction to allopurinol.
(17) Antitumor drugs (e.g., cyclophosphamide, methotrexate): Concurrent administration with thiazide diuretics (including hydrochlorothiazide) may reduce renal excretion of cytotoxic drugs and thus enhance the myelosuppressive effect.
(18) Calcium salts: Concurrent administration of thiazide diuretics may cause hypercalcemia by increasing calcium reabsorption in the tubules.
(19) Diazoxide and beta-blockers: Thiazide diuretics may increase the hyperglycemic effect of diazoxide. Concomitant use of beta-blockers and thiazide diuretics may increase the risk of hyperglycemia.
(20) Iodine contrast media: In case of dehydration caused by diuretics, the risk of acute renal failure increases, especially when high doses of iodine agents are used together. Rehydration is required prior to administration.
7. Administration to pregnant and lactating women
1) Because of the mechanism of action of angiotensin II receptor antagonists, the risk to the fetus cannot be ignored. There are reports that exposure to ACE inhibitors (a specific group of drugs that act on the renin-angiotensin-aldosterone system (RAAS)) during the second and third trimesters of pregnancy causes fetal development damage and death. Additionally, retrospective data suggest that use of ACE inhibitors in the first trimester of pregnancy is associated with a potential risk of birth defects.
Fetal renal perfusion is established in the second trimester of pregnancy and is influenced by the renin-angiotensin system, so taking valsartan during the second or third trimester increases the risk. The use of drugs that act directly on the renin-angiotensin system during the second and third trimesters of pregnancy has been shown to be associated with fetal and neonatal harm, including hypotension, neonatal cranial hypoplasia, anuria, reversible or irreversible renal failure, and death. Oligohydramnios has been reported and has been shown to be associated with fetal limb contractures, craniofacial malformations, and pulmonary hypoplasia. Premature birth, poor intrauterine growth, and patent ductus arteriosus have also been reported, although the relationship to drug exposure is unclear.
Intrauterine exposure to thiazide diuretics, including hydrochlorothiazide, may cause fetal or neonatal jaundice, thrombocytopenia and other adverse reactions seen in adults. Spontaneous abortion, oligohydramnios and neonatal renal dysfunction have been reported following inadvertent valsartan exposure during pregnancy. All neonates exposed to the medicine in utero should be assessed for urine output, hyperkalemia and blood pressure. If necessary, take medical measures to remove the medicine from the circulation. As with other medicines that act directly on the renin–angiotensin–aldosterone system (RAAS), this medicine must not be used during pregnancy or by women planning pregnancy. Stop treatment immediately if pregnancy is confirmed. In rare cases, affecting fewer than 1 in 1,000 pregnant women, no alternative to a medicine acting on the renin–angiotensin system may be available. In such cases, when prescribing a RAAS-acting medicine to a woman who could become pregnant, the physician must explain its potential risks during pregnancy and perform serial ultrasound examinations to assess the intra-amniotic environment.
If oligohydramnios is observed, this drug should be discontinued except to save the life of the pregnant woman. Depending on the gestational age, contraction stress testing (CST), nonstress testing (NST), or biophysical profiling (BPP) testing may be appropriate. However, patients and doctors should be aware that oligohydramnios may not appear even after irreversible damage has already occurred to the fetus.
Infants who have been exposed in utero to angiotensin II receptor antagonists should be closely monitored for hypotension, oliguria, and hyperkalemia. If oliguria is present, attention should be paid to maintaining blood pressure and renal perfusion. Exchange transfusion or dialysis may be necessary to reverse low blood pressure and replace renal function.
2) It has not been determined whether valsartan is secreted into breast milk in humans, but secretion of valsartan into breast milk was confirmed in tests on rats. Hydrochlorothiazide crosses the placenta and is excreted in breast milk in humans. Therefore, it is not advisable for nursing mothers to use this drug.
3) There is no information on the effects of valsartan or hydrochlorothiazide on human fertility. There is no information on reproductive function in this drug, but non-clinical studies conducted with each component of valsartan and hydrochlorothiazide did not show any effect on reproductive function.
8. Administration to children
Safety and efficacy in children have not been established.
9. Administration to elderly people
In comparative clinical trials of this drug, no overall differences in the efficacy and safety of valsartan-hydrochlorothiazide were observed between elderly and non-elderly groups.
10. Effect on clinical test values
1) A decrease in serum potassium of more than 20% occurred in 3.7% of patients receiving this drug and 3.1% of placebo patients (refer to the cautious administration section).
2) The following results occurred in valsartan monotherapy, but did not occur when administering this drug. : Rarely, a decrease in hemoglobin and hematocrit was observed.
3) The results of the controlled clinical trial showed a significant (>20%) decrease in hematocrit and hemoglobin by 0.8% and 0.4%, respectively. On the other hand, in the case of placebo, both decreased by 0.1%.
4) As a result of the controlled clinical trial, significant increases in serum creatine, potassium, and total bilirubin concentrations were 0.8%, 4.4%, and 6.0% for patients administered valsartan, and 1.6%, 6.4%, and 12.9% for ACE inhibitors. Additionally, in controlled clinical trials, creatinine and BUN increases were observed in 1.9% and 14.7% of patients administered this drug, respectively, and 0.4% and 6.3% of patients treated with placebo, respectively.
5) Occasionally, an increase in liver function test values has been reported with the administration of valsartan.
6) Special monitoring of clinical laboratory values is not necessary for patients with essential hypertension taking this drug.
7) Neutropenia was observed in 0.1% of patients receiving this drug and in 0.4% of patients receiving placebo.
11. Treatment in case of overdose
1) Data on overdose in humans are limited. Symptoms that are likely to appear in overdose are hypotension and tachycardia. : Overdosage of valsartan can cause significant hypotension, which can lead to decreased consciousness, circulatory collapse, and shock. Immediately after taking it, induce vomiting, otherwise, inject saline solution intravenously.
2) Overdosage of hydrochlorothiazide may cause the following symptoms. : Nausea, drowsiness, hypovolemia, electrolyte abnormalities related to arrhythmia, muscle spasms. Measures should be taken depending on the time after overdose and the symptoms or severity of symptoms, but restoration of circulatory stability is most important. If it is immediately after taking it, induce vomiting, and if a long time has passed since taking it, administer an appropriate amount of medicinal charcoal.
3) In case of low blood pressure, place the patient supine and perform plasma replacement as quickly as possible. Valsartan is not removed by hemodialysis due to its strong binding to plasma proteins, but hydrochlorothiazide can be removed by dialysis.
12. Precautions for storage and handling
1) Keep out of reach of children.
2) Store away from moisture.
3) Taking medicine out of its original container and storing it in another container may cause accidents due to misuse of the medicine or cause a decrease in the quality of the medicine, so put it in the original container and keep it tightly closed.
13. Others
In preclinical safety studies of valsartan, hydrochlorothiazide, and valsartan/hydrochlorothiazide using several species of animals, there was no evidence of systemic or specific organ toxicity. High doses of valsartan/hydrochlorothiazide (100/31.25 to 600/187.5 mg/kg) decreased red blood cell counts (erythrocytes, hemoglobin, and hematocrit) and altered renal hemodynamics in rats (moderate to severe increases in blood urea, increases in blood potassium and magnesium, mild increases in urine volume and electrolytes, and slight tubular abnormalities). Basophils, hypertrophy of afferent arteriolar hypertrophy at highest dose). In marmosets (30:9.375 to 400:125mg/kg), the changes were quite similar but more severe. In particular, at high doses, nephropathy occurred in the kidneys, including increases in urea and creatinine.
Hypertrophy of renal juxtaglomerular cells was also observed in both species. All changes are considered to be due to the synergistic (rather than additive, approximately 10-fold potentiating compared to valsartan alone) pharmacological action of valsartan/hydrochlorothiazide, resulting in prolonged hypotension, particularly in marmosets. Therapeutic doses of valsartan-hydrochlorothiazide are unlikely to be associated with renal glomerular hypertrophy in humans. The main preclinical safety findings are due to the pharmacological actions of the drugs, which appear to act synergistically, and there is no evidence of other interactions between the two drugs. In clinical trials, the actions of the two drugs were additive, and preclinical results did not indicate clinical significance.
There was no evidence of valsartan/hydrochlorothiazide interaction, and therefore the combination was not tested for mutagenicity, chromosomal aberrations, or carcinogenicity. However, valsartan and hydrochlorothiazide were tested for mutagenesis, chromosomal abnormality, and carcinogenicity, respectively, and all showed negative results.
5. How to save
Store in an airtight container, avoiding moisture below 30℃.
6. Packaging unit
30 tablets/bottle
7. Expiration date
36 months from date of manufacture
Product Updates
Total 6items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 6 | Valtrep Plus Tab. | Precautions for use | 2026.02.19 | PDF0147_201105412_Precautions for use_Waltrep Plus Tablet.pdf |
| 5 | Valtrep Plus Tab. | Precautions for use | 2026.02.12 | PDF0443_201105412_Precautions for use_Waltrep Plus Tablet.pdf |
| 4 | Valtrep Plus Tab. | Precautions for use | 2023.02.07 | PDFPrecautions for using Valtrep Plus Tablet (including change comparison table).pdf |
| 3 | Valtrep Plus Tab. | Precautions for use | 2019.01.25 | PDF0231_201105412_Precautions for use (Waltrep Plus tablet).pdf |
| 2 | Valtrep Plus Tab. | Valtrep Plus Tablet (Precautions for use) | 2017.02.15 | HWPUnification adjustment of valsartan hydrochlorothiazide complex tablets |
| 1 | Valtrep Plus Tab. | Valtrep Plus Tablet (efficacy, dosage, usage instructions... | 2012.12.31 | HWPWaltrep Plus Tablet_Permission Change Order.hwp |